

**REMARKS**


Claims 1-24 are cancelled. Claims 25-58 are added. The new claims are supported by the specification and claims as originally filed, including by original claims 1 and 2 and the specification at page 9, lines 15-24. There is no new matter added, and entry of the amendment is respectfully requested.

In response to the restriction requirement, Applicants respectfully submit that above-amended claims. Applicants also elect the invention directed to variant amylases. Applicants further elect the species of alterations corresponding to R118K, R320K and R458K.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: September 21, 2004

  
Elias J. Lambris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097